US5866344A
(en)
*
|
1991-11-15 |
1999-02-02 |
Board Of Regents, The University Of Texas System |
Antibody selection methods using cell surface expressed libraries
|
US20030036092A1
(en)
*
|
1991-11-15 |
2003-02-20 |
Board Of Regents, The University Of Texas System |
Directed evolution of enzymes and antibodies
|
PT744958E
(pt)
|
1994-01-31 |
2003-11-28 |
Univ Boston |
Bancos de anticorpos policlonais
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6696251B1
(en)
*
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US8207093B2
(en)
|
1997-01-21 |
2012-06-26 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
US6261804B1
(en)
*
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
ES2373110T3
(es)
|
1997-01-21 |
2012-01-31 |
The General Hospital Corporation |
Selección de proteínas usando fusiones de arn-proteína.
|
JP2002514919A
(ja)
*
|
1997-04-04 |
2002-05-21 |
バイオサイト ダイアグノスティックス,インコーポレイテッド |
多価ライブラリーおよびポリクローナルライブラリー
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
US6555310B1
(en)
|
1997-04-04 |
2003-04-29 |
Biosite Diagnostics, Inc. |
Polyclonal libraries
|
EP1025256A2
(de)
*
|
1997-10-09 |
2000-08-09 |
Ixsys, Incorporated |
Verfahren zur identifizierung von mit rezeptoren gebundenen ligenden
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
US6100063A
(en)
*
|
1998-02-12 |
2000-08-08 |
Novo Nordisk A/S |
Procaryotic cell comprising at least two copies of a gene
|
AU3072799A
(en)
|
1998-03-19 |
1999-10-11 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
IL138668A0
(en)
|
1998-04-03 |
2001-10-31 |
Phylos Inc |
Addressable protein arrays
|
AU5488399A
(en)
*
|
1998-08-17 |
2000-03-06 |
Phylos, Inc. |
Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
|
DE69941193D1
(de)
|
1998-08-17 |
2009-09-10 |
Bristol Myers Squibb Co |
Identifizierung von verbindung-protein wechselwirkungen mit bibliotheken von gekoppelten protein-nukleinsäure-molekülen
|
PT1137812E
(pt)
*
|
1998-12-02 |
2007-05-31 |
Adnexus Therapeutics Inc |
Fusões adn-proteína e suas utilizações
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
CA2361929C
(en)
*
|
1999-03-16 |
2009-05-26 |
Kao Corporation |
Liquid deodorant
|
ATE295430T1
(de)
*
|
1999-03-31 |
2005-05-15 |
Us Gov Health & Human Serv |
Typisierung von humanen enteroviren
|
WO2000072869A1
(en)
|
1999-06-01 |
2000-12-07 |
Phylos, Inc. |
Methods for producing 5'-nucleic acid-protein conjugates
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20070111259A1
(en)
*
|
1999-10-02 |
2007-05-17 |
Medarex, Inc. |
Human antibodies
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
US8048416B2
(en)
|
1999-10-08 |
2011-11-01 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7419792B2
(en)
|
1999-10-08 |
2008-09-02 |
Arius Research Inc. |
Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
|
US8071072B2
(en)
|
1999-10-08 |
2011-12-06 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US6657048B2
(en)
|
1999-10-08 |
2003-12-02 |
Arius Research, Inc. |
Individualized anti-cancer antibodies
|
US7252821B2
(en)
|
1999-10-08 |
2007-08-07 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7442776B2
(en)
|
1999-10-08 |
2008-10-28 |
Young David S F |
Cancerous disease modifying antibodies
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
WO2001053539A1
(en)
|
2000-01-24 |
2001-07-26 |
Phylos, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
US7022479B2
(en)
*
|
2000-01-24 |
2006-04-04 |
Compound Therapeutics, Inc. |
Sensitive, multiplexed diagnostic assays for protein analysis
|
ES2529300T3
(es)
|
2000-04-12 |
2015-02-18 |
Novozymes Biopharma Dk A/S |
Proteínas de fusión de albúmina
|
US7439330B2
(en)
*
|
2000-05-08 |
2008-10-21 |
President And Fellows Of Harvard College |
Anti-glycated CD59 antibodies and uses thereof
|
US6835545B2
(en)
|
2000-05-08 |
2004-12-28 |
President And Fellows Of Harvard College |
Methods, products and treatments for diabetes
|
CA2410586C
(en)
*
|
2000-05-26 |
2010-07-20 |
Symphogen A/S |
Recombinant or purified polyclonal antibodies for treating allergy
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1294949A4
(de)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Menschlicher tumornekrosefaktor delta und epsilon
|
US6849259B2
(en)
|
2000-06-16 |
2005-02-01 |
Symphogen A/S |
Polyclonal antibody composition for treating allergy
|
KR101287395B1
(ko)
|
2000-06-16 |
2014-11-04 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 BLyS에 결합하는 항체
|
US6638312B2
(en)
*
|
2000-08-04 |
2003-10-28 |
Depuy Orthopaedics, Inc. |
Reinforced small intestinal submucosa (SIS)
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
EP1360208B1
(de)
*
|
2000-11-08 |
2008-05-07 |
Arius Research, Inc. |
Verfahren zur herstellung zytotoxischen antikörper gegen krebs
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US7858559B2
(en)
*
|
2000-11-17 |
2010-12-28 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US7442777B2
(en)
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
AU2002220275A1
(en)
*
|
2000-12-08 |
2002-06-18 |
The Board Of Trustees Of The University Of Illinois |
Mutated class ii major histocompatibility proteins
|
EP2357187A1
(de)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
WO2002086096A2
(en)
*
|
2001-01-23 |
2002-10-31 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
CA2437811A1
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
EP1360310A2
(de)
*
|
2001-02-13 |
2003-11-12 |
University Of Florida |
Bidirektionaler dualer promotorkomplex mit verstärkter promotoraktivität zur transgenen expression in eukaroynten
|
JP2004533815A
(ja)
|
2001-03-14 |
2004-11-11 |
ミリアド・ジェネティックス・インコーポレイテッド |
Tsg101−gag相互作用およびその使用
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP1572874B1
(de)
|
2001-05-25 |
2013-09-18 |
Human Genome Sciences, Inc. |
An trail-rezeptoren immunspezifisch bindende antikörper
|
WO2003019137A2
(en)
*
|
2001-08-22 |
2003-03-06 |
Steven Kessler |
Methods for screening antibody-producing cells on heterogenous antigen substrates
|
WO2003028625A2
(en)
*
|
2001-08-22 |
2003-04-10 |
Steven Kessler |
Methods for screening monoclonal antibodies on heterogeneous antigen substrates
|
US20060073095A1
(en)
*
|
2001-08-22 |
2006-04-06 |
Steven Kessler |
Methods for screening antibody-producing cells on heterogeneous antigen substrates
|
US6696271B2
(en)
*
|
2001-08-23 |
2004-02-24 |
The Regents Of The University Of California |
Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
|
WO2003019192A1
(en)
*
|
2001-08-27 |
2003-03-06 |
The Trustees Of Boston University |
Apparatus, composition and method for proteome profiling
|
DE60232672D1
(de)
|
2001-10-01 |
2009-07-30 |
Dyax Corp |
Mehrkettige eukaryontische display-vektoren und deren verwendungen
|
US20040005709A1
(en)
*
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
EP2261250B1
(de)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin Fusionsproteine
|
EP1757305A3
(de)
*
|
2001-12-21 |
2007-03-14 |
Arius Research, Inc. |
Individualisierte Antikörper gegen Krebs
|
CA2471206A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Arius Research, Inc. |
Individualized anti-cancer antibodies
|
US7244592B2
(en)
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
CN1186445C
(zh)
*
|
2002-03-15 |
2005-01-26 |
陈志南 |
抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7541150B2
(en)
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
US7012100B1
(en)
*
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
CN100418981C
(zh)
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
DE60319259T2
(de)
*
|
2002-06-14 |
2009-03-05 |
Dyax Corp., Cambridge |
Rekombination von nukleinsäurebibliotheksmitgliedern
|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
ATE386111T1
(de)
*
|
2002-09-18 |
2008-03-15 |
Univ Pennsylvania |
Zusammensetzungen, verfahren und kits zum nachweis eines antigens auf einer zelle und in einem biologischen gemisch
|
PT2301965E
(pt)
|
2002-10-16 |
2015-05-20 |
Purdue Pharma Lp |
Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização
|
US20050147962A1
(en)
*
|
2002-11-19 |
2005-07-07 |
Wagstrom Christopher R. |
Display of dimeric proteins on phage
|
CN100383244C
(zh)
*
|
2003-01-07 |
2008-04-23 |
西福根有限公司 |
用于生产重组多克隆蛋白质的方法
|
NZ541458A
(en)
*
|
2003-01-07 |
2006-04-28 |
Symphogen As |
Method for manufacturing recombinant polyclonal proteins
|
US20060275766A1
(en)
*
|
2003-01-07 |
2006-12-07 |
Haurum John S |
Method for manufacturing recombinant polyclonal proteins
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2516455C
(en)
|
2003-02-20 |
2012-05-01 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
MXPA05009913A
(es)
|
2003-03-19 |
2005-11-04 |
Biogen Idec Inc |
Proteina enlazadora del receptor nogo.
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
PT1625166E
(pt)
|
2003-05-12 |
2015-08-20 |
Helion Biotech Aps |
Anticorpos para masp-2
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
AU2004242614B2
(en)
|
2003-05-30 |
2011-09-22 |
Merus N.V. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
JP4934426B2
(ja)
|
2003-08-18 |
2012-05-16 |
メディミューン,エルエルシー |
抗体のヒト化
|
TWI333977B
(en)
|
2003-09-18 |
2010-12-01 |
Symphogen As |
Method for linking sequences of interest
|
US20050148029A1
(en)
*
|
2003-09-29 |
2005-07-07 |
Biosite, Inc. |
Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
|
US20050164238A1
(en)
*
|
2003-09-29 |
2005-07-28 |
Biosite, Inc. |
Methods and compositions for the diagnosis of sepsis
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
DK1983000T3
(en)
|
2003-11-21 |
2015-12-07 |
Ucb Biopharma Sprl |
A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
|
CA2550933A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
AU2005205412B2
(en)
|
2004-01-20 |
2011-08-11 |
Merus N.V. |
Mixtures of binding proteins
|
SI1729795T1
(sl)
|
2004-02-09 |
2016-04-29 |
Human Genome Sciences, Inc. |
Albuminski fuzijski proteini
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
US20050260710A1
(en)
*
|
2004-03-31 |
2005-11-24 |
Sekisui Chemical Co. Ltd. |
Methods for producing recombinant polyclonal immunoglobulins
|
CA2955027A1
(en)
|
2004-04-15 |
2005-11-10 |
University Of Florida Research Foundation, Inc. |
Neural proteins as biomarkers for nervous system injury and other neural disorders
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
EP1771483A1
(de)
|
2004-07-20 |
2007-04-11 |
Symphogen A/S |
Rekombinanter polyklonaler anti-rhesus-d-antikörper und herstellungsverfahren
|
MX2007000551A
(es)
*
|
2004-07-20 |
2007-03-30 |
Symphogen As |
Procedimiento para la caracterizacion estructural de una proteina policlonal recombinante o una linea celular policlonal.
|
EP1789070B1
(de)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in der neuronalen funktion
|
WO2006017694A1
(en)
*
|
2004-08-05 |
2006-02-16 |
Biosite Incorporated |
Compositions and methods for phage display of polypeptides
|
JP2008513540A
(ja)
|
2004-09-21 |
2008-05-01 |
メディミューン,インコーポレーテッド |
呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン,インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
US7833725B2
(en)
*
|
2005-01-06 |
2010-11-16 |
President And Fellows Of Harvard College |
Mass spectrometric methods and products
|
WO2006086242A2
(en)
|
2005-02-07 |
2006-08-17 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
EP1858545A2
(de)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
US7618809B2
(en)
|
2005-03-23 |
2009-11-17 |
Gebing Ronald A |
Microarrayer with coaxial multiple punches
|
EP1707628B1
(de)
*
|
2005-03-30 |
2009-11-11 |
Sekisui Chemical Co., Ltd. |
Verfahren zur Produktion von rekombinanten polyklonalen Immunglobulinen
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2012018687A1
(en)
|
2010-08-02 |
2012-02-09 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP2221316A1
(de)
|
2005-05-05 |
2010-08-25 |
Duke University |
CD19-Antikörper-Therapie für Autoimmunerkrankungen
|
EP2295066B1
(de)
|
2005-05-25 |
2016-04-27 |
CureDM Group Holdings, LLC |
Peptide, Derivate und Analoge davon sowie Verfahren zu ihrer Anwendung
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
PT1904104E
(pt)
|
2005-07-08 |
2013-11-21 |
Biogen Idec Inc |
Anticorpos sp35 e suas utilizações
|
EP1920057A4
(de)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
Polysaccharid-synthasen
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
JP5364870B2
(ja)
|
2005-08-19 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
EP2500354A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
ATE546160T1
(de)
|
2005-09-14 |
2012-03-15 |
Ucb Pharma Sa |
Antikörper-kammpolymer-konjugat
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
US8249814B2
(en)
|
2005-10-21 |
2012-08-21 |
Genenews Inc. |
Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
|
AU2006311828B2
(en)
|
2005-11-04 |
2013-07-11 |
Biogen Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
PL1954718T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
|
WO2007064972A2
(en)
|
2005-11-30 |
2007-06-07 |
Abbott Laboratories |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
CA2631181A1
(en)
|
2005-12-02 |
2007-06-07 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
SI1960430T1
(sl)
|
2005-12-09 |
2015-01-30 |
Ucb Pharma, S.A. |
Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
PT1981902E
(pt)
|
2006-01-27 |
2015-11-02 |
Biogen Ma Inc |
Antagonistas dos recetores nogo
|
WO2007103469A2
(en)
|
2006-03-06 |
2007-09-13 |
Aeres Biomedical Ltd. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
IL302157A
(en)
|
2006-03-15 |
2023-06-01 |
Alexion Pharma Inc |
Treatment of patients with paroxysmal nocturnal hemoglobinuria by a complement inhibitor
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
EP2505209A1
(de)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
KR20170014023A
(ko)
|
2006-07-05 |
2017-02-07 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP2061810B1
(de)
|
2006-09-05 |
2014-11-12 |
Alexion Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung antikörper-vermittelter nervenleiden
|
KR101625961B1
(ko)
|
2006-09-08 |
2016-05-31 |
애브비 바하마스 리미티드 |
인터루킨-13 결합 단백질
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
BRPI0717474A2
(pt)
*
|
2006-10-20 |
2014-03-11 |
Arizona Board Of Regentes For And On Behalf Of Arizona State University |
Cianobactéria modificada
|
EP2087007A2
(de)
|
2006-11-09 |
2009-08-12 |
Irm Llc |
Agonistische trkb-antikörper und ihre verwendung
|
US8785400B2
(en)
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
EP2687232A1
(de)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Verfahren zur Behandlung von systemischem Lupus erythematodes
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
UA99120C2
(en)
|
2007-01-09 |
2012-07-25 |
Байоджэн Айдэк Ма Инк. |
Sp35 antibodies and uses thereof
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
EP2124952A2
(de)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
EP2121920B1
(de)
|
2007-03-01 |
2011-08-24 |
Symphogen A/S |
Verfahren zur klonierung verwandter antikörper
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
SI2125894T1
(sl)
|
2007-03-22 |
2019-05-31 |
Biogen Ma Inc. |
Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
EP2145902A3
(de)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
SG194368A1
(en)
|
2007-05-04 |
2013-11-29 |
Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
CN103223167B
(zh)
|
2007-05-14 |
2015-06-17 |
米迪缪尼有限公司 |
降低嗜酸性粒细胞水平的方法
|
CN103694351A
(zh)
|
2007-06-05 |
2014-04-02 |
耶鲁大学 |
受体酪氨酸激酶抑制剂及其使用方法
|
KR101799337B1
(ko)
|
2007-06-21 |
2017-12-20 |
마크로제닉스, 인크. |
공유결합형 디아바디 및 이것의 사용
|
ES2534434T3
(es)
|
2007-08-30 |
2015-04-22 |
Curedm Group Holdings, Llc |
Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
US9096855B2
(en)
|
2007-10-18 |
2015-08-04 |
Cell Signaling Technology, Inc. |
Translocation and mutant ROS kinase in human non-small cell lung carcinoma
|
RU2530561C2
(ru)
|
2007-11-05 |
2014-10-10 |
Медиммун, Ллк |
Способы лечения склеродермии
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
US8821863B2
(en)
|
2008-01-11 |
2014-09-02 |
Gene Techno Science Co., Ltd. |
Humanized anti-α 9 integrin antibodies and the uses thereof
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
CN102037007A
(zh)
*
|
2008-01-25 |
2011-04-27 |
奥尔胡斯大学 |
选择性外部位点抑制papp-a对igfbp-4的活性
|
AU2009212273B2
(en)
|
2008-02-08 |
2014-07-31 |
Astrazeneca Ab |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
JP6014706B2
(ja)
*
|
2008-02-14 |
2016-10-25 |
株式会社イーベック |
hGM−CSFに結合するモノクローナル抗体および前記抗体を含む医薬組成物
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
AU2009231991B2
(en)
|
2008-04-02 |
2014-09-25 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
EP2252631B1
(de)
|
2008-04-02 |
2016-04-13 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikörper und verfahren zu ihrer verwendung
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
WO2009126934A2
(en)
|
2008-04-11 |
2009-10-15 |
Seattle Genetics, Inc. |
Detection and tratment of pancreatic, ovarian and other cancers
|
EP2280998A1
(de)
*
|
2008-04-23 |
2011-02-09 |
Symphogen A/S |
Verfahren zur herstellung eines polyklonalen proteins
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
CA2723219A1
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP3002299A1
(de)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
EP2307042B1
(de)
|
2008-06-25 |
2014-03-26 |
H. Lundbeck A/S |
Modulierung des trpv : vps10p domänen-rezeptorsystems zur behandlung von schmerzen
|
EP2810654A1
(de)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin-E2 bindende Proteine und ihre Verwendung
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
WO2010005570A2
(en)
|
2008-07-09 |
2010-01-14 |
Biogen Idec Ma Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
AU2009293640A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of 2G12 -derived domain exchanged antibodies
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
US20120251502A1
(en)
|
2008-10-24 |
2012-10-04 |
The Government of the US as Represented by the Secretary of the Dept. of health |
Human Ebola Virus Species and Compositions and Methods Thereof
|
EP2364103B1
(de)
*
|
2008-11-10 |
2013-01-02 |
Kids II, Inc. |
Elektromagnetische kinderwippe
|
CN102438652B
(zh)
|
2008-11-12 |
2014-08-13 |
米迪缪尼有限公司 |
抗体制剂
|
US20110287088A1
(en)
|
2008-12-03 |
2011-11-24 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
MX2011006416A
(es)
|
2008-12-19 |
2011-07-12 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
EP3165537A1
(de)
|
2008-12-19 |
2017-05-10 |
H. Lundbeck A/S |
Modulation der vps-10-domänen-rezeptor-familie für die behandlung von psychischen und verhaltensstörungen
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010085510A1
(en)
|
2009-01-20 |
2010-07-29 |
Zadeh Homayoun H |
Antibody mediated osseous regeneration
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
EP2881402B1
(de)
|
2009-02-12 |
2017-05-10 |
Cell Signaling Technology, Inc. |
Expression mutanter ROS bei menschlichem Leberkrebs
|
AR075504A1
(es)
|
2009-02-17 |
2011-04-06 |
Ucb Pharma Sa |
Moleculas de anticuerpos que tienen especificidad para el ox40 humano
|
PE20121094A1
(es)
|
2009-03-05 |
2012-09-13 |
Abbvie Inc |
Proteinas de union a il-17
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP2406285B1
(de)
|
2009-03-10 |
2016-03-09 |
Gene Techno Science Co., Ltd. |
Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
MX2011011075A
(es)
|
2009-04-20 |
2011-11-04 |
Oxford Biotherapeutics Ltd |
Anticuerpos especificos para cadherina-17.
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
WO2011020079A1
(en)
|
2009-08-13 |
2011-02-17 |
Calmune Corporation |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
MX2012002605A
(es)
|
2009-08-29 |
2012-04-02 |
Abbott Lab |
Proteinas terapeutico de union a dll4.
|
IN2012DN02737A
(de)
|
2009-09-01 |
2015-09-11 |
Abbott Lab |
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US20120244170A1
(en)
|
2009-09-22 |
2012-09-27 |
Rafal Ciosk |
Treating cancer by modulating mex-3
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
CA2775959A1
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US8734798B2
(en)
|
2009-10-27 |
2014-05-27 |
Ucb Pharma S.A. |
Function modifying NAv 1.7 antibodies
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
US9244063B2
(en)
|
2009-11-11 |
2016-01-26 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
NZ619512A
(en)
|
2010-02-08 |
2014-10-31 |
Regeneron Pharma |
Common light chain mouse
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
WO2011117653A1
(en)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP2561076A1
(de)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulation von xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
ES2552954T3
(es)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
EP2569335B1
(de)
|
2010-05-14 |
2018-08-22 |
Orega Biotech |
Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
|
WO2011143562A2
(en)
|
2010-05-14 |
2011-11-17 |
Abbott Laboratories |
Il-1 binding proteins
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
NZ603488A
(en)
|
2010-07-09 |
2015-02-27 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
SG188190A1
(en)
|
2010-08-03 |
2013-04-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
EP3333188B1
(de)
|
2010-08-19 |
2022-02-09 |
Zoetis Belgium S.A. |
Anti-ngf-antikörper und deren verwendung
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
US9068006B2
(en)
|
2010-08-25 |
2015-06-30 |
President And Fellows Of Harvard College |
Glycated CD59 peptides, their preparation, and uses thereof
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
WO2012032143A1
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
AU2012206431B2
(en)
|
2011-01-14 |
2015-04-30 |
UCB Biopharma SRL |
Antibody molecules which bind IL-17A and IL-17F
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
EP2699264B1
(de)
|
2011-04-20 |
2018-03-14 |
Medlmmune, LLC |
Antikörper und andere moleküle zur bindung von b7-h1 und pd-1
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
US9452219B2
(en)
|
2011-06-02 |
2016-09-27 |
University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
JP6058645B2
(ja)
|
2011-06-10 |
2017-01-11 |
メディミューン,エルエルシー |
抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用
|
MY160826A
(en)
|
2011-06-28 |
2017-03-31 |
Berlin-Chemie Ag |
Antibodies to bone marrow stromal antigen 1
|
PT2726094T
(pt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Alvo terapêutico e de diagnóstico
|
EP3574919A1
(de)
|
2011-07-13 |
2019-12-04 |
AbbVie Inc. |
Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
LT3572517T
(lt)
|
2011-08-05 |
2021-04-26 |
Regeneron Pharmaceuticals, Inc. |
Humanizuotos universalios lengvosios grandinės pelės
|
DK2739310T3
(en)
|
2011-08-05 |
2018-07-16 |
Res Found Dev |
Improved methods and compositions for modulating OLFML3-mediated angiogenesis
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
ES2908046T3
(es)
|
2011-09-09 |
2022-04-27 |
Medimmune Ltd |
Anticuerpos anti-siglec-15 y usos de los mismos.
|
SG11201401791WA
(en)
|
2011-10-24 |
2014-08-28 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773373B1
(de)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Verfahren zur blockierung eines krebsstammzellenwachstums
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
LT2776466T
(lt)
|
2011-11-11 |
2017-11-27 |
Ucb Biopharma Sprl |
Albuminą prisijungiantys antikūnai ir jų prisijungimo fragmentai
|
JP6336397B2
(ja)
|
2011-12-14 |
2018-06-06 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
EP3800200A1
(de)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
MX352772B
(es)
|
2012-01-27 |
2017-12-07 |
Abbvie Deutschland |
Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas.
|
EP3575794A1
(de)
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detektion und behandlung von cd30+karzinomen
|
SI2814842T1
(sl)
|
2012-02-15 |
2018-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
JP6411218B2
(ja)
|
2012-02-15 |
2018-10-24 |
ノヴォ ノルディスク アー/エス |
骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
WO2013142808A1
(en)
|
2012-03-23 |
2013-09-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
WO2013143026A1
(en)
*
|
2012-03-31 |
2013-10-03 |
Abmart (Shanghai) Co., Ltd |
Peptide and antibody libraries and uses thereof
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013158859A1
(en)
|
2012-04-18 |
2013-10-24 |
Cell Signaling Technology, Inc. |
Egfr and ros1 in cancer
|
SG11201406770WA
(en)
|
2012-04-20 |
2014-11-27 |
Merus B V |
Methods and means for the production of ig-like molecules
|
EA030716B1
(ru)
|
2012-05-14 |
2018-09-28 |
Байоджен Ма Инк. |
Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
|
JP6122948B2
(ja)
|
2012-05-15 |
2017-04-26 |
モルフォテック, インコーポレイテッド |
胃癌の治療のための方法
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
EP2867674B1
(de)
|
2012-06-28 |
2018-10-10 |
UCB Biopharma SPRL |
Verfahren zur identifikation von verbindungen von therapeutischem interesse
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
CN102851338A
(zh)
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
DK2912064T3
(da)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
Jam-c-antistoffer og fremgangsmåder til behandling af cancer
|
BR112015009961B1
(pt)
|
2012-11-01 |
2020-10-20 |
Abbvie Inc. |
proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
RU2691428C2
(ru)
|
2012-12-21 |
2019-06-13 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела к h7cr
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
JP6382935B2
(ja)
|
2013-03-15 |
2018-08-29 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
抗egfr抗体薬物複合体製剤
|
SG11201507432XA
(en)
|
2013-03-15 |
2015-10-29 |
Abbvie Inc |
Antibody drug conjugate (adc) purification
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
SG10201913751RA
(en)
|
2013-05-06 |
2020-03-30 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
CA2914566A1
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
CA2921652A1
(en)
|
2013-08-21 |
2015-02-26 |
Manuel A. Riquelme |
Compositions and methods for targeting connexin hemichannels
|
KR102553717B1
(ko)
|
2013-08-26 |
2023-07-11 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
WO2015066027A2
(en)
|
2013-10-28 |
2015-05-07 |
Dots Devices, Inc. |
Allergen detection
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
WO2015143414A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
US9546214B2
(en)
|
2014-04-04 |
2017-01-17 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
EP3157535A1
(de)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
PE20170192A1
(es)
|
2014-07-17 |
2017-03-16 |
Novo Nordisk As |
Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
|
EP3172325B1
(de)
|
2014-07-22 |
2023-06-28 |
The University of Notre Dame du Lac |
Molekulare konstrukte und verwendungen davon
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
EP3200829B1
(de)
|
2014-10-01 |
2023-12-06 |
Medimmune, LLC |
Verfahren zum konjugieren eines polypeptids
|
RU2021125449A
(ru)
|
2014-10-01 |
2021-09-16 |
Медиммьюн Лимитед |
Антитела к тикагрелору и способы применения
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US20170306046A1
(en)
|
2014-11-12 |
2017-10-26 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
ES2934940T3
(es)
|
2014-12-11 |
2023-02-28 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
CA2972048C
(en)
|
2014-12-22 |
2023-03-07 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
EP3242893A1
(de)
|
2015-01-08 |
2017-11-15 |
Biogen MA Inc. |
Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
|
HUE061070T2
(hu)
|
2015-03-03 |
2023-05-28 |
Kymab Ltd |
Ellenanyagok, alkalmazások és eljárások
|
EP3271403A1
(de)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Nichtmenschliche tiere zur selektion von leichtkettigen variablen regionen zur antigenbindung
|
EP3273994B1
(de)
|
2015-03-27 |
2021-12-01 |
University of Southern California |
Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
US10814012B2
(en)
|
2015-04-29 |
2020-10-27 |
University Of South Australia |
Compositions and methods for administering antibodies
|
WO2016176573A1
(en)
|
2015-04-30 |
2016-11-03 |
Board Of Regents, The University Of Texas System |
Antibacterial polypeptide libraries and methods for screening the same
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
CN107847594B
(zh)
|
2015-05-06 |
2022-04-15 |
詹森生物科技公司 |
前列腺特异性膜抗原(psma)双特异性结合剂及其用途
|
US10259882B2
(en)
|
2015-05-07 |
2019-04-16 |
Agenus Inc. |
Anti-OX40 antibodies
|
EA039951B1
(ru)
|
2015-05-27 |
2022-03-31 |
Юсб Биофарма Спрл |
Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
|
MX2017015046A
(es)
|
2015-05-29 |
2018-05-17 |
Agenus Inc |
Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
|
AU2016270640B2
(en)
|
2015-05-29 |
2022-03-10 |
Abbvie Inc. |
Anti-CD40 antibodies and uses thereof
|
US10711064B2
(en)
|
2015-06-04 |
2020-07-14 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
EP3569244A1
(de)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3-gerichtete car-zellen zur immuntherapie
|
SG11201802887PA
(en)
|
2015-10-27 |
2018-05-30 |
Ucb Biopharma Sprl |
Methods of treatment using anti-il-17a/f antibodies
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
IL302822A
(en)
|
2015-11-12 |
2023-07-01 |
Seagen Inc |
Compounds interacting with glycans and methods of use
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
BR112018067951A2
(pt)
|
2016-03-10 |
2019-02-05 |
Viela Bio Inc |
moléculas que se ligam a ilt7 e métodos de uso destas
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
JP7241541B2
(ja)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ,インコーポレイテッド |
グリコシル化pd-l1に特異的な二重機能抗体およびその使用方法
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
WO2017205465A2
(en)
|
2016-05-24 |
2017-11-30 |
Griswold Karl Edwin |
Antibodies and methods of making same
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
WO2018067468A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
AU2017343621B2
(en)
|
2016-10-11 |
2021-12-02 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
SG11201903842YA
(en)
|
2016-11-02 |
2019-05-30 |
Immunogen Inc |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
EP3551660B1
(de)
|
2016-12-07 |
2023-09-13 |
Agenus Inc. |
Anti-ctla-4-antikörper und verfahren zur verwendung davon
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
JP2020510671A
(ja)
|
2017-03-03 |
2020-04-09 |
シアトル ジェネティックス, インコーポレイテッド |
グリカン相互作用化合物および使用の方法
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
CA3053409A1
(en)
|
2017-04-15 |
2018-10-18 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ApoC3抗体およびその使用方法
|
CN110603449A
(zh)
|
2017-04-28 |
2019-12-20 |
雅培实验室 |
用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
|
HUE062927T2
(hu)
|
2017-05-01 |
2023-12-28 |
Agenus Inc |
Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
JP7269182B2
(ja)
|
2017-05-30 |
2023-05-08 |
アボット・ラボラトリーズ |
心臓トロポニンi及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
|
EP3630835A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
JP2020526745A
(ja)
|
2017-07-03 |
2020-08-31 |
アボット・ラボラトリーズAbbott Laboratories |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
MA49565A
(fr)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics Llc |
Anticorps agonistes qui lient cd137 humain et leurs utilisations
|
AU2018298881A1
(en)
|
2017-07-14 |
2020-01-16 |
Immatics Biotechnologies Gmbh |
Improved dual specificity polypeptide molecule
|
EP3684811A2
(de)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
US11464784B2
(en)
|
2017-09-15 |
2022-10-11 |
The Regents Of The University Of California |
Inhibition of aminocylase 3 (AA3) in the treatment of cancer
|
CA3075376A1
(en)
|
2017-09-22 |
2019-03-28 |
Wuxi Biologics Ireland Limited. |
Bispecific cd3/cd19 polypeptide complexes
|
SG11202002261VA
(en)
|
2017-09-22 |
2020-04-29 |
Wuxi Biologics Ireland Ltd |
Novel bispecific polypeptide complexes
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
TW201922294A
(zh)
|
2017-10-31 |
2019-06-16 |
美商伊繆諾金公司 |
抗體-藥物結合物與阿糖胞苷之組合治療
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
JP7165193B2
(ja)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ヒト組織因子を標的とするヒト化抗体
|
EP3721233A2
(de)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Verfahren zur unterstützung bei der diagnose und bewertung eines patienten, der eine orthopädische verletzung erlitten hat und der eine verletzung des kopfes wie eine leichte traumatische hirnverletzung (tbi) hat oder möglicherweise erlitten hat, unter verwendung eines glialen fibrillären sauren proteins (gfap) und/oder einer ubiquitin-carboxy-terminalen hydrolase l1 (uch-l1)
|
US11016105B2
(en)
|
2017-12-09 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
WO2019169212A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
US10982002B2
(en)
|
2018-03-12 |
2021-04-20 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
BR112020018480B1
(pt)
|
2018-03-14 |
2022-09-27 |
Surface Oncology, Inc |
Usos de anticorpos que se ligam a cd39 no tratamento de câncer
|
MA52094A
(fr)
|
2018-03-22 |
2021-01-27 |
Adimab Llc |
Anticorps anti-il-27 et leurs utilisations
|
TWI790370B
(zh)
|
2018-04-02 |
2023-01-21 |
美商必治妥美雅史谷比公司 |
抗trem-1抗體及其用途
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
EP3784274A1
(de)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
US20200109195A1
(en)
|
2018-05-21 |
2020-04-09 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
MX2020013808A
(es)
|
2018-06-18 |
2021-05-27 |
UCB Biopharma SRL |
Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Vistaに対する受容体
|
EP3833443A1
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigenbindende mittel, die cd277 binden, und verwendungen davon
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
EP3856773A1
(de)
|
2018-09-28 |
2021-08-04 |
Kyowa Kirin Co., Ltd. |
Il-36-antikörper und verwendungen davon
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
WO2020102387A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
JP2022514903A
(ja)
|
2018-12-20 |
2022-02-16 |
協和キリン株式会社 |
Fn14抗体及びその使用
|
EP3911679A1
(de)
|
2019-01-16 |
2021-11-24 |
Compass Therapeutics LLC |
Formulierungen von antikörpern zur bindung von humanem cd137 und verwendungen davon
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
BR112022002761A2
(pt)
|
2019-08-12 |
2022-08-09 |
Aptevo Res & Development Llc |
Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
|
JP2022545741A
(ja)
|
2019-08-30 |
2022-10-28 |
アジェナス インコーポレイテッド |
抗cd96抗体およびその使用方法
|
US20220306736A1
(en)
|
2019-09-04 |
2022-09-29 |
Y-Biologics Inc. |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
BR112022002351A2
(pt)
|
2019-09-16 |
2022-07-19 |
Surface Oncology Inc |
Composições e métodos de anticorpo anti-cd39
|
US20210115127A1
(en)
|
2019-09-25 |
2021-04-22 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN114929278A
(zh)
|
2020-01-06 |
2022-08-19 |
瓦西尼斯公司 |
抗ccr8抗体及其用途
|
US20230061973A1
(en)
|
2020-02-05 |
2023-03-02 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
EP4103612A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispezifische antikörper gegen cd9
|
US20230151108A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
US20230192900A1
(en)
|
2020-02-13 |
2023-06-22 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
US20230096030A1
(en)
|
2020-02-13 |
2023-03-30 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
US20230125234A1
(en)
|
2020-02-13 |
2023-04-27 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
JP2023513834A
(ja)
|
2020-02-18 |
2023-04-03 |
アレクトル エルエルシー |
Pilra抗体及びその使用方法
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
CN115697491A
(zh)
|
2020-05-17 |
2023-02-03 |
阿斯利康(英国)有限公司 |
Sars-cov-2抗体及其选择和使用方法
|
EP4182343A2
(de)
|
2020-07-20 |
2023-05-24 |
AstraZeneca UK Limited |
Sars-cov-2-proteine, anti-sars-cov-2-antikörper und verfahren zur verwendung davon
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
US11725052B2
(en)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
AU2021359092A1
(en)
|
2020-10-15 |
2023-06-01 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
EP4229081A1
(de)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
JP2023551907A
(ja)
|
2020-12-01 |
2023-12-13 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
腫瘍関連抗原及びcd3結合タンパク質、関連する組成物、及び方法
|
EP4271998A1
(de)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
|
CA3204731A1
(en)
|
2021-01-13 |
2022-07-21 |
John T. POIRIER |
Anti-dll3 antibody-drug conjugate
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
TW202302645A
(zh)
|
2021-03-03 |
2023-01-16 |
法商皮爾法伯製藥公司 |
抗vsig4抗體或抗原結合片段及其用途
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
AU2022270361A1
(en)
|
2021-05-05 |
2023-11-16 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
KR20240005809A
(ko)
|
2021-05-07 |
2024-01-12 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
CA3220629A1
(en)
|
2021-05-28 |
2022-12-01 |
Tobin J. CAMMETT |
Methods for detecting cm-tma biomarkers
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
WO2023007472A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|